Abbott Laboratories

Humira Will Help AbbVie Prevail, A Great Buy With Low Valuation
Humira Will Help AbbVie Prevail, A Great Buy With Low Valuation
Seeking Alpha
Humira
AbbVie
Abbott Laboratories
Flag link:
AbbVie's Shares Are More Appealing Than Abbott's Following The Spin-Off
AbbVie's Shares Are More Appealing Than Abbott's Following The Spin-Off
Seeking Alpha
Abbott Laboratories
AbbVie
Flag link:
Abbott Gets Xience Xpedition Approval
Abbott Gets Xience Xpedition Approval
Yahoo/Zacks
Abbott Laboratories
Xience Xpedition
regulatory
FDA
Flag link:
2012 Roundup -- HCV Treatments
2012 Roundup -- HCV Treatments
Motley Fool
HCV
Vertex Pharmaceuticals
Merck
Gilead Sciences
Abbott Laboratories
hepatitis C
Achillion
Idenix
JNJ
GSK
Flag link:
How Abbott Labs Succeeded in 2012
How Abbott Labs Succeeded in 2012
Motley Fool
Abbott Laboratories
Flag link:
Abbott Spinoff AbbVie Begins Trading to Determine Value
Abbott Spinoff AbbVie Begins Trading to Determine Value
Bloomberg
AbbVie
Abbott Laboratories
Flag link:
AbbVie's Life After Abbott
AbbVie's Life After Abbott
Motley Fool
AbbVie
Abbott Laboratories
Flag link:
Medtronic, Dexcom and Abbott Offer New Products to a Growing Diabetic Population in Europe, a €5 Billion + Market
Medtronic, Dexcom and Abbott Offer New Products to a Growing Diabetic Population in Europe, a €5 Billion + Market
diabetes
type 2 diabetes
Medtronic
Abbott Laboratories
DexCom
Flag link:
Abbott Laboratories: Today's Featured Drugs Winner
Abbott Laboratories: Today's Featured Drugs Winner
The Street
Abbott Laboratories
Flag link:
5 Drug Hopefuls That Are Going to Change Your Life: Part 2
5 Drug Hopefuls That Are Going to Change Your Life: Part 2
Motley Fool
Gilead Sciences
sofosbuvir
hepatitis C
Bristol-Myers Squibb
BMS-986094
Idenix
IDX-184
Abbott Laboratories
Achillion
ACH-3102
Flag link:
This Week in Biotech: Part 1 (The Hep-C Chronicles)
This Week in Biotech: Part 1 (The Hep-C Chronicles)
Motley Fool
Gilead Sciences
Abbott Laboratories
Idenix
Achillion
hepatitis C
Flag link:
Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting®
Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting®
Yahoo/PR NewsWire
Abbott Laboratories
hepatitis C
Flag link:
For Hep C Investors, What Goes Around Comes Around
For Hep C Investors, What Goes Around Comes Around
Motley Fool
hepatitis C
Vertex Pharmaceuticals
Gilead Sciences
Abbott Laboratories
Idenix
Achillion
Flag link:
Abbott: Cash In On This Big Pharma's Recent Pullback Now
Abbott: Cash In On This Big Pharma's Recent Pullback Now
Seeking Alpha
Abbott Laboratories
Flag link:
Pharmaceutical Stocks Are All-of-a-Sudden Hot Again: Read About Drugs and Dividends
Pharmaceutical Stocks Are All-of-a-Sudden Hot Again: Read About Drugs and Dividends
Forbes
Merck
Eli Lilly
Abbott Laboratories
Novartis
Pfizer
Flag link:
Abbott Tenders for Bonds Before $16 Billion in Debt Issuance
Abbott Tenders for Bonds Before $16 Billion in Debt Issuance
Bloomberg
Abbott Laboratories
Flag link:
S&P downgrades Abbott Labs credit rating
S&P downgrades Abbott Labs credit rating
Yahoo/AP
Abbott Laboratories
Flag link:
What's Driving Abbott Labs Today
What's Driving Abbott Labs Today
Motley Fool
Abbott Laboratories
Flag link:
3 Big Events for 1 Big Pharma (video)
3 Big Events for 1 Big Pharma (video)
Motley Fool
Abbott Laboratories
Flag link:
Abbott Labs Shares Slide on Kidney Study
Abbott Labs Shares Slide on Kidney Study
PharmPro
Abbott Laboratories
Bardoxolone
Reata Pharmaceuticals
Flag link:

Pages